Hamad Bin Khalifa University#s Qatar Biomedical Research Institute Forms New Partnership With Harvard Stem Cell Institute

Food and Healthcare Press Releases Tuesday October 9, 2018 13:54
DOHA, Qatar--9 Oct--PRNewswire/InfoQuest
  • New partnership to boost region's first cell-therapy program to tackle diabetes

Qatar Biomedical Research Institute (QBRI), a premier research institute under Hamad Bin Khalifa University (HBKU), has signed a collaborative research and training agreement with the Harvard Stem Cell Institute (HSCI) in Boston, USA. The five-year initiative includes technical training and research in stem cell biology, which are essential for discovering viable treatments for diabetes.

(Photo: https://mma.prnewswire.com/media/765535/QBRI_HBKU_Agreement.jpg )

The prevalence of diabetes type 1 and 2 is a rising global healthcare challenge. Recent advances in stem cell research, led by HSCI scientists, are set to help both type 1 and type 2 diabetes patients cope with their condition by producing new insulin-producing cells. Such advances can be extended to address many diseases that have a major impact on society.

In this new collaboration, QBRI scientists will work closely with HSCI researchers to exchange knowledge and best practice, and to accelerate the translation of discoveries into clinical applications. In addition to building scientific capacity in the region, the partnership will support ground-breaking research in stem cell biology. Clinical trials that arise from these endeavors will be conducted in collaboration with QBRI's major stakeholders, including Qatar-based Hamad Medical Corporation and Sidra Medicine.

"This partnership with HSCI is another step towards our primary goal of conducting research that has tangible, meaningful impact on the wider community. Innovation and entrepreneurial vision are at the core of QBRI's activities. This partnership with leading stem cell researchers at Harvard is a crucial step in spurring progress towards our strategic vision, to solve some of the critical challenges facing Qatar and the region. Thanks to this agreement, newly recruited investigators at QBRI will be engaging in ground-breaking research within the largest collaborative network of stem-cell researchers in the world," said Dr. Omar El Agnaf, acting executive director at QBRI.

HSCI - a network of 1,000 scientists at Harvard University and its eight affiliated hospitals - is a champion of research in stem cell biology and regenerative medicine. It is a powerful partner for realizing QBRI's strategic plan to develop the first cell-therapy program in the region.

Brock Reeve, executive director of HSCI, said: "Qatar has been proactive in building scientific capacity in the Middle East, and its current focus on stem cell biology shows its commitment to supporting progress in personalized medicine. Partnering with QBRI allows us to share knowledge and expertise efficiently through advanced training, and to conduct meaningful research with a focus on translation. We are really looking forward to working together, and to seeing what new opportunities for discovery arise as a result."

QBRI aims to address major health challenges over the long term by supporting scientific research into the molecular basis of various diseases, and biomedical research that seeks to translate those insights into solutions for diabetes, neurological disorders, and cancer. The partnership with HSCI will facilitate progress in these areas.

Research is integral to HBKU's mission to help build high-level skills capacity in Qatar. This new partnership allows the university to actively leverage synergies with local and international organizations to foster a world-class education ecosystem that promotes scientific discovery and benefits humankind.

About Hamad Bin Khalifa University
Innovating Today, Shaping Tomorrow
For more information about HBKU, visit http://www.hbku.edu.qa
About the Harvard Stem Cell Institute
For more information about HSCI, visit: hsci.harvard.edu
Contact: Sylvana Georgie, Sylvanag@bljworldwie.com, +974-70218268
Source: HBKU

Latest Press Release

BioNet reports on persistence of antibody responses of recombinant pertussis vaccines in the Lancet Infectious Diseases

Publications report the sustained higher antibody responses of BioNet acellular pertussis vaccines containing genetically inactivated pertussis toxin (PTgen) and the new opportunities to control the resurgence of whooping cough disease BioNet announced...

The Menarini Group Announces Meropenem/vaborbactam European Marketing Authorization

- Meropenem/vaborbactam approved on 20th November 2018 by the European Commission for clinical use in adult patients with difficult-to-treat infections - The first combination of a carbapenem and a beta-lactamase inhibitor approved for clinical use in...

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

- FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of first clinical data in BTC - BTC is a group of rare, aggressive...

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

- Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological profiles - Evaluation to include...

Vitality-linked Insurers to Get 100 million People 20% More Active by 2025

Building on the results of the largest behaviour change study on physical activity, Vitality and its global network of insurers have collectively committed to improving the health of millions over the next seven years. This is in line with the World...

Related Topics